🔬 The Persistent Challenge of Lung Cancer Treatment

Lung cancer stands as the leading cause of cancer-related deaths worldwide, claiming millions of lives each year. In the United States alone, it accounts for approximately 25% of all cancer fatalities. Among the various types, non-small cell lung cancer (NSCLC), which encompasses about 80-85% of cases, poses particularly tough hurdles for medical professionals. Unlike small cell lung cancer, NSCLC tends to grow and spread more slowly but often develops resistance to standard therapies like chemotherapy, targeted drugs, radiation, and even immunotherapy.

Patients initially respond to treatments such as cisplatin or doxorubicin-based regimens, but many tumors adapt, becoming resistant. This resistance stems from complex biological mechanisms within cancer cells that allow them to pump out drugs, evade cell death, and metastasize aggressively. Survival rates reflect this grim reality: the five-year overall survival for advanced NSCLC hovers around 28%, underscoring the urgent need for innovative strategies to overcome these barriers.

Understanding NSCLC requires grasping its subtypes, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, often linked to factors like smoking, environmental exposures, and genetic mutations. Current approaches focus on precision medicine, targeting mutations like EGFR or ALK, but a significant portion of patients lack these actionable alterations, leaving them reliant on traditional chemotherapy with limited long-term success.

The Biology of Growth Hormone and Its Receptor

Growth hormone (GH), produced by the pituitary gland, plays a crucial role in childhood development, metabolism, muscle growth, and tissue repair throughout life. It exerts its effects by binding to the growth hormone receptor (GHR), a protein embedded in cell membranes across various tissues, including the liver, muscle, and fat.

Upon binding, GH activates intracellular signaling pathways, primarily the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, along with others like PI3K-AKT and MAPK. This cascade influences gene expression, promoting cell proliferation, survival, and differentiation. While essential for normal physiology, dysregulated GH-GHR signaling has been implicated in aging, diabetes, and notably, cancer progression.

In cancer contexts, elevated GH or GHR activity can fuel tumor growth by enhancing cell division, inhibiting programmed cell death (apoptosis), and facilitating metastasis. Researchers have observed this in breast, prostate, and colorectal cancers, but its precise role in lung cancer remained underexplored until recent investigations.

Ohio University's Breakthrough Discovery

Researchers at Ohio University, led by renowned Goll-Ohio Eminent Scholar John J. Kopchick, Ph.D., and graduate student Arshad Ahmad, have uncovered a compelling link between GHR and NSCLC aggressiveness. Their study, published in the International Journal of Molecular Sciences, analyzed vast transcriptomic datasets from hundreds of NSCLC patients, including those from The Cancer Genome Atlas (TCGA).

Key revelation: NSCLC tumors express significantly higher levels of GHR compared to healthy lung tissue. Patients with high tumoral GHR faced markedly shorter survival times—around 36 to 40 months—versus about 66 months for those with low GHR expression. This correlation held across large cohorts, painting GHR as a biomarker for poor prognosis.

The team's work builds on Kopchick's decades-long expertise; he discovered pegvisomant in 1987, an FDA-approved drug for acromegaly—a condition of GH excess. Now, they're repurposing it for oncology, a strategy gaining traction for its established safety profile.

Photo by The DK Photography on Unsplash

Mechanisms: How GHR Fuels Chemotherapy Resistance

Diving deeper, the Ohio University team pinpointed how GH-GHR signaling drives resistance. In laboratory experiments using human NSCLC cell lines like H1299, H1703, and H1734, as well as mouse LLC1 cells, GH exposure boosted tumor cell proliferation over 96 hours. It upregulated ATP-binding cassette (ABC) transporters—proteins like ABCB1 (P-glycoprotein) and ABCG2 that act as cellular pumps, expelling chemotherapy drugs before they can kill the cells.

Additionally, GH triggered epithelial-to-mesenchymal transition (EMT), a process where cancer cells lose their structured, stationary form and gain migratory, invasive traits. Markers such as ZEB1, SNAIL, vimentin, and N-cadherin surged, enabling metastasis. GH also activated anti-apoptotic genes like BCL2 and matrix metalloproteinases (MMPs) for tissue invasion, alongside TGF-β pathways.

• ABC transporters efflux drugs, reducing intracellular concentrations.
• EMT promotes spread to distant sites like bones or brain.
• Suppressed apoptosis allows cancer cells to survive treatment.

High GHR tumors showed enriched expression of these resistance genes, with sex-specific patterns noted in TCGA data.

Pegvisomant: Reversing Resistance and Enhancing Chemo

Enter pegvisomant (Somavert), the GHR antagonist. In vitro, it nullified GH's effects spectacularly. When pretreated with pegvisomant, NSCLC cells became hypersensitive to cisplatin and doxorubicin. The half-maximal inhibitory concentration (IC50)—the drug dose needed to kill half the cells—dropped dramatically: up to 4.4-fold for cisplatin in H1734 cells and 3.2-fold for doxorubicin in H1299 cells.

Pegvisomant suppressed ABC transporters, EMT markers, migration (via wound-healing assays), and invasion (fluorometric assays). GH increased IC50 by over 3-fold in some lines, but pegvisomant restored sensitivity, suggesting lower chemo doses could suffice, minimizing side effects like nausea, hair loss, and neuropathy.Read the full study here.

Kopchick noted, “These findings suggest that growth hormone signaling helps drive aggressive and therapy-resistant lung cancer. By blocking the growth hormone receptor, we may be able to improve the effectiveness of existing treatments.”

From Lab to Clinic: Next Steps and Potential Impact

While promising, this research is preclinical—cell-based. The team has prior success combining pegvisomant with chemo in mouse models of melanoma, pancreatic, and liver cancers, shrinking tumors effectively. Upcoming: implanting NSCLC cells in mice to test combo therapies.

Success could fast-track clinical trials, leveraging pegvisomant's approval. For patients, this means hope for second-line options post-resistance. Explore research jobs in oncology at institutions like Ohio University driving such innovations.

Broader implications: GHR targeting might synergize with immunotherapies like PD-1 inhibitors, common in NSCLC. It addresses unmet needs in mutation-negative cases, potentially extending survival beyond current limits.

Photo by Bruno Brikmanis-Jurjans on Unsplash

Context in Lung Cancer Landscape and Patient Advice

Lung cancer treatments evolve rapidly, with breakthroughs in targeted therapies for KRAS or MET mutations. Yet, resistance remains universal. GH-GHR fits into endocrine-oncology, akin to blocking estrogen in breast cancer.

Patients facing resistance should discuss biomarkers like GHR expression via tumor biopsies. Clinical trials via clinical research opportunities offer access to novel combos. Lifestyle factors—quitting smoking, nutrition—complement therapies.

Ohio University news release details the study's origins.

Looking Ahead: Repurposing and Precision Oncology

Pegvisomant's profile—safe, injectable—eases translation. Challenges include optimizing dosing, biomarkers for patient selection, and combo toxicities. Future: GHR SNPs (genetic variants) as predictors, per prior studies linking them to lung cancer risk.

This Ohio breakthrough exemplifies academic impact. Institutions foster such work; rate professors like Kopchick on Rate My Professor or pursue higher ed jobs in biomedical sciences.

In summary, GHR targeting heralds a new era for NSCLC, blending endocrinology and oncology. Share your thoughts in comments—what questions do you have for researchers?